Effect of Imatinib on Bone Marrow Morphology and Angiogenesis in Chronic Myeloid Leukemia by Neetu Pandey, Geeta Yadav, Rashmi Kushwaha, Shailendra Prasad Verma, Uma Shankar Singh, Ashutosh Kumar, Prabhaker Mishra

“…Imatinib inhibits BCR-ABL tyrosine kinase produced due to reciprocal translocation t(9;22) in neoplastic CML cells. …”
Get full text

Detection of The TNFSF Members BAFF, APRIL, TWEAK and Their Receptors in Normal Kidney and Renal Cell Carcinomas by Vassiliki Pelekanou, George Notas, Katerina Theodoropoulou, Marilena Kampa, Dimitrios Takos, Vassilia-Ismini Alexaki, Jelena Radojicic, Frank Sofras, Andreas Tsapis, Efstathios N. Stathopoulos, Elias Castanas

“…Therapeutic modalities targeting VEGF, PDGF, and c-kit using tyrosine kinase inhibitors and m-TOR using specific biologic factors are in development. …”
Get full text

Expression and significance of CEMIP and CYP11B2 in serum in women with foetal growth restriction by Yang Yue, Fang Fang Zhou, Jia Rong Zhang, Fu Xu

“…CEMIP (95%CI: 0.802–0.921, P < 0.001) and CYP11B2 (95%CI: 0.795–0.907, P < 0.001) mRNA expression in serum and soluble fms like tyrosine kinase-1 (sFLT1)/placental growth factor (PlGF) ratio (95%CI: 0.866–0.974, P < 0.001) were independent predictors of FGR, and CEMIP (r = −0.578, P = 0.001) and CYP11B2 (r = −0.602, P < 0.001) mRNA expression in serum were negatively correlated with sFLT1/PlGF ratio. …”
Get full text

How Much Time Should Be Waited and What Are the Main Findings to Evaluate the Hepatocellular Carcinoma Response to Regorafenib? A Real-Life Experience by Gustavo Hideki Kawanami, Leopoldo Katsuda, Thiara Barcelos Rocha, Fabio da Silva Yamashiro, Leonardo Pelafsky, Xingshun Qi, Fernando Gomes Romeiro

“…In addition, some clinical and imaging findings can be deemed as predictors of good response to tyrosine kinase inhibitors.…”
Get full text

Case report: A panorama gene profile of ovarian cancer metastasized to axillary lymph node by Yu Xia, Yu Huang, Zheng Liu, Siyuan Song, Yi Wang, Yi Wang, Jing Luo

“…Further analysis of NGS identified two novel missense mutations, D326E in BTK (Bruton’s tyrosine kinase) at SH2 domain and D251E in EPHA5 (EPH receptor A5), along with other known cancer- associated mutations. …”
Get full text

Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study by Geke Zhu, Han Zhou, Wanying Wang, Yongbo Ma, Xiangtao Nie, Wenjing Qi, Lei Hao, Xiuming Guo

“…During the 8-week follow-up, in GMG patients, whether positive for acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) antibodies, the overall efficacy was significant. …”
Get full text

Pharmacovigilance imbalance analysis of VEGFR-TKI-related taste and smell disorders by Zhong-hua Fu, Chenglong Zhao, Yaqin Wang, Lei Zhang, Lei Wang

“…The advent of targeted drugs such as vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) has significantly extended the survival time of cancer patients, and thus widely used in clinical practice. …”
Get full text

Gene Expression Pattern and Regulatory Network of α-Toxin Treatment in Bombyx mori by Tieshan Feng, Ping Lin, Jiao Gong, Dong Cheng, Xi Yang, Quan Zhang, Tingcai Cheng

“…The upregulated genes in the midgut were mainly involved in peptidoglycan catabolic process and tyrosine kinase signaling pathway, whereas the downregulated genes were mainly involved in chitin metabolic pathways. …”
Get full text

A novel imatinib analogue inhibitor of chronic myeloid leukaemia: design, synthesis and characterization—explanation of its folded conformation by Rodolfo Moreno-Fuquen, Juan F. Avellaneda-Tamayo, Kevin Arango-Daraviña, Javier Ellena, Alan R. Kennedy

“…Chronic myeloid leukaemia (CML) is primarily treated using imatinib mesylate, a tyrosine kinase inhibitor (TKI) targeting the BCR::ABL1 oncoprotein. …”
Get full text

Midostaurin shapes macroclonal and microclonal evolution of FLT3-mutated acute myeloid leukemia by Romane Joudinaud, Augustin Boudry, Laurène Fenwarth, Sandrine Geffroy, Mikaël Salson, Hervé Dombret, Céline Berthon, Arnaud Pigneux, Delphine Lebon, Pierre Peterlin, Simon Bouzy, Pascale Flandrin-Gresta, Emmanuelle Tavernier, Martin Carre, Sylvie Tondeur, Lamya Haddaoui, Raphael Itzykson, Sarah Bertoli, Audrey Bidet, Eric Delabesse, Mathilde Hunault, Christian Récher, Claude Preudhomme, Nicolas Duployez, Pierre-Yves Dumas

“…Abstract: Despite the use of midostaurin (MIDO) with intensive chemotherapy (ICT) as frontline treatment for Fms-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia (AML), complete remission rates are close to 60% to 70%, and relapses occur in >40% of cases. …”
Get full text

Chronic Myeloid Leukemia: Part II—Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective by Ehab L. Atallah, Rodrigo Maegawa, Dominick Latremouille-Viau, Carmine Rossi, Annie Guérin

“…**Background:** Tyrosine kinase inhibitors (TKIs) are the standard-of-care treatment for chronic myeloid leukemia in chronic phase (CML-CP). …”
Get full text

Novel genes involved in vascular dysfunction of the middle temporal gyrus in Alzheimer’s disease: transcriptomics combined with machine learning analysis by Meiling Wang, Aojie He, Yubing Kang, Zhaojun Wang, Yahui He, Kahleong Lim, Chengwu Zhang, Li Lu

“…Two subtypes of middle temporal gyrus cells showed significant alteration in AD: endothelial cells with high expression of Erb-B2 receptor tyrosine kinase 4 (ERBB4high) and pericytes with high expression of angiopoietin-like 4 (ANGPTL4high). …”
Get full text

The Impact of Targeted Therapies on Red Blood Cell Aggregation in Patients with Chronic Lymphocytic Leukemia Evaluated Using Software Image Flow Analysis by Anika Alexandrova-Watanabe, Emilia Abadjieva, Lidia Gartcheva, Ariana Langari, Miroslava Ivanova, Margarita Guenova, Tihomir Tiankov, Velichka Strijkova, Sashka Krumova, Svetla Todinova

“…Despite advances in therapies targeting Bruton’s tyrosine kinase and anti-apoptotic protein BCL-2, little is known about their effect on red blood cell (RBC) aggregation in blood flow. …”
Get full text

Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention by Rodrigo Fonseca, Yuan Xiao Zhu, Laura A. Bruins, Joseph Ahmann, Cecilia de Bonolo Campos, Esteban Braggio, Xianfeng Chen, Mariano Arribas, Susie Darvish, Seth Welsh, Erin Meermeier, Kiran K. Mangalaparthi, Richard K. Kandasamy, Greg Ahmann, J. Erin Wiedmeier-Nutor, Akhilesh Pandey, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca

“…Upstream signaling pathways, including growth factor receptor tyrosine kinase (RTK) and phosphoinositide-3-kinase (PI3K) were implicated in this dysregulation. …”
Get full text

Magnetic Resonance Imaging Combined with Serological Markers Improves the Diagnosis of Placenta Previa with Placenta Accreta Spectrum by Ying Wang, Zhengdong Hou, Bingqing Xia, Xianjing Xie, Ying He

“…The aim of this study was to evaluate the accuracy of magnetic resonance imaging (MRI) combined with three serological markers (alpha-fetoprotein [AFP], creatine kinase [CK], and soluble fms-like tyrosine kinase-1 [sFlt-1]) for the diagnosis of PP with PAS. …”
Get full text

Inhibition of TFF3 synergizes with c-MET inhibitors to decrease the CSC-like phenotype and metastatic burden in ER+HER2+ mammary carcinoma by Chuyu He, Xuejuan Wang, Yi-Shiou Chiou, Basappa Basappa, Tao Zhu, Vijay Pandey, Peter E. Lobie

“…Furthermore, a high-throughput combinatorial anti-cancer compound library screening revealed that AMPC preferentially synergized with receptor tyrosine kinase c-MET inhibitors (c-METis) to reduce cell survival and the CSC-like phenotype. …”
Get full text

Epigenetics of suicidal behavior by R. N. Mustafin, A. V. Kazantseva, R. F. Enikeeva, Yu. D. Davydova, S. B. Malykh, V. V. Viktorov, E. K. Khusnutdinova

“…The analysis of a brain obtained from suicide victims, representing a unique tool for the analysis of modified genomic processes, revealed a wide range of reprogramming patterns of DNA methylation in promoters of the genes of polyamine (OAZ1, OAZ2, AMD1, ARG2, SKA2), serotonergic (SLC6A4) and GABAergic (GABRA1) systems, HPA-axis (GR, NR3C1), tyrosine kinase (TrkB) receptors, brain-derived neurotrophic factor (BDNF). …”
Get full text

Evaluation of Safety and Efficacy of a Single Lorecivivint Injection in Patients with Knee Osteoarthritis: A Multicenter, Observational Extension Trial by Christopher J. Swearingen, Jeyanesh R. S. Tambiah, Ismail Simsek, Heli Ghandehari, Sarah Kennedy, Yusuf Yazici

“…Abstract Introduction Lorecivivint (LOR), a CDC-like kinase/dual-specificity tyrosine kinase (CLK/DYRK) inhibitor thought to modulate inflammatory and Wnt pathways, is being developed as a potential intra-articular knee osteoarthritis (OA) treatment. …”
Get full text

Enhancing immunotherapy efficacy in colorectal cancer: targeting the FGR-AKT-SP1-DKK1 axis with DCC-2036 (Rebastinib) by Xiguang Chen, Qiting Zeng, Liyang Yin, Bingru Yan, Chen Wu, Jianbo Feng, Ying Wu, Jun He, Wenjun Ding, Jing Zhong, Yingying Shen, Xuyu Zu

“…Abstract This research demonstrates that DCC-2036 (Rebastinib), a potent third-generation tyrosine kinase inhibitor (TKI), effectively suppresses tumor growth in colorectal cancer (CRC) models with functional immune systems. …”
Get full text

Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors by Guihong Yang, Yimei Wang, Huimin Zhao, Ziyi Jiang, Shansong Zheng, Mingjing Ge, Meimei Si, Xiaoyan Kang

“…Abstract Iruplinalkib (WX‐0593), a selective oral ALK/ROS1 tyrosine kinase inhibitor, was approved in China as first‐line therapy for ALK‐positive non‐small‐cell lung cancer (NSCLC) and for the treatment of locally advanced or metastatic ALK‐positive NSCLC that has progressed following crizotinib therapy. …”
Get full text